In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

The chip maker's chief executive reiterated confidence in the strength of AI-driven semiconductor demand. How Moderna Went From Pandemic Hero to Vaccine Victim The biotech's mRNA vaccines were lauded ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.